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What this paper adds 
 
What is already known about this subject? 
 Severe obesity presents an increasing source of clinical and economic strain to 
healthcare providers. 
 Most adults who underwent bariatric surgery experience improved health and 
psychological functioning with bariatric surgery considered cost-effective. 
 Data on bariatric surgery for adolescents are extremely limited (and all are from 
Australia or the US), and it is difficult to draw conclusions as to whether such 
intervention is cost-effective. 
What this study adds? 
 We compared the costs and quality-adjusted life years (QALYs) of two types of surgery 
(laparoscopic Roux en Y Gastric Bypass (RYGB) and laparoscopic Sleeve Gastrectomy 
(SG)) versus no surgery in adolescents with severe obesity from the perspective of the 
UK National Health Service (NHS). 
 Bariatric surgery is more costly than no surgery; however it markedly improved quality 
of life. 
 Bariatric surgery is a cost-effective alternative to no surgery. 
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Abstract 
Background 
Evidence shows that surgery for severe obesity in adults improves health and psychological 
functioning, and is cost-effective. Data on bariatric surgery for adolescents with severe obesity 
are extremely limited, with no evidence on cost-effectiveness. 
 
Aim  
To evaluate the lifetime cost-effectiveness of bariatric surgery compared with no surgery in 
adolescents with severe obesity from the UK’s NHS perspective. 
 
Methods 
Eighteen adolescents with BMI ≥40kg/m2 who underwent bariatric surgery (laparoscopic Roux 
en Y Gastric Bypass (RYGB) (N=9), and laparoscopic Sleeve Gastrectomy (SG) (N=9)) at 
University College London Hospitals (UCLH) between January 2008 and December 2013 were 
included. We used a Markov cohort model to compare the lifetime expected costs and quality-
adjusted life years (QALYs) between bariatric surgery and no surgery. 
 
Results 
Mean cost of RYGB and SG procedures were £7,100 and £7,312, respectively. 
 
For RYGB versus no surgery, the incremental cost/QALY was £2,018 (95% CI £1,942 to 
£2,042) for males and £2,005 (95% CI £1,974 to £2,031) for females.  
For SG versus no surgery, the incremental cost/QALY was £1,978 (95% CI £1,954 to £2,002) 
for males and £1,941 (95% CI £1,915 to £1,969) for females. 
Conclusions 
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Bariatric surgery in adolescents with severe obesity is cost-effective; it is more costly than no 
surgery however it markedly improved quality of life. 
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Introduction 
Data from the National Child Measurement Programme (NCMP) in England showed that in 
2012/2013, severe obesity (Body Mass Index (BMI) ≥UK90 99.6th centile) equivalent to the 
adult bariatric threshold of 35kg/m2 was found in 1.2% of girls and 1.5% of boys aged 10-11 
years [1]. Severe obesity presents an increasing source of clinical and economic strain to 
healthcare providers. 
 
The economic burden of obesity is substantial. In England, the costs of overweight and obesity 
to the health system have been calculated to be £4.2 billion per annum [2].  
 
Much of this burden is driven by a number of co-morbidities which occur at a higher prevalence 
among obese young people including type 2 diabetes, hyperlipidaemia, hypertension, sleep 
apnoea, as well as significant psychosocial consequences and the increased likelihood of 
becoming obese adults [3-5]. Thus the medical, psychological and economic consequences of 
obesity represent a significant challenge to healthcare systems. 
 
Bariatric surgery is the only available intervention that results in large magnitudes of weight 
loss. In adults, conservative treatment of severe obesity (BMI ≥40kg/m2) largely produced poor 
long-term results, whereas surgery for obesity usually results in significant permanent weight 
loss. After obesity surgery, most patients experience improved health and psychological 
functioning [6] with bariatric surgery considered cost-effective [7]. 
 
Outcomes of adolescent bariatric surgery appear similar to those in adults although high quality 
long term data is limited. Systematic reviews suggest that surgery is highly effective for short-
term BMI reduction [8] and improves quality of life [9]. However, there is very little published 
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data on the cost-effectiveness of bariatric surgery in adolescents, and none from the UK. In 
England, National Institute for Health and Care Excellence (NICE) guidance [10] notes that 
bariatric surgery is not generally recommended for children and young people 
(Recommendation 1.10.12), but may be considered in exceptional circumstances in those who 
have reached psychological maturity (Recommendation 1.10.13) and have BMI ≥40kg/m2 or 
BMI ≥35kg/m2 with significant co-morbidities that would be improved if they lost weight 
(Recommendation 1.10.1). 
 
We assessed the lifetime cost-effectiveness of bariatric surgery (laparoscopic Roux en Y 
Gastric Bypass (RYGB) or laparoscopic Sleeve Gastrectomy (SG)) compared with no 
intervention, using data from a cohort of 18 adolescents with severe obesity undergoing surgery 
in one NHS centre in the UK. 
 
Methods 
Framework of Economic Model 
We conducted a cost-utility analysis using lifetime expected costs and quality-adjusted life 
years (QALYs) that compared bariatric surgery with no surgery. 
 
A Markov model was used to project costs, body mass index (BMI) and QALYs over lifetime. 
The Markov transition model comprised five health states such as “no co-morbidity”, 
“diabetes”, “coronary heart disease (CHD)”, “stroke” and “colon cancer”, and death (Figure 
1).  
 
Adolescents with severe obesity (BMI ≥40kg/m2) enter the model in the “no co-morbidity” 
health state at age of 18 years. BMI starting point for adolescents in group RYGB was 
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48.3kg/m2 and for those in SG group was 60.03kg/m2. The model consisted of yearly cycles. 
At the end of each one-year period, a proportion of the cohort can move from one health state 
to another or stay in the same health state. We assumed that adolescents remain in the co-
morbid health states until they die (age-specific death or obesity-related co-morbidity death). 
The disease transition probabilities are based on disease progression related to age, gender, 
BMI and cycle. The model is run over 82 years (until patients are 100 years old or have died) 
to estimate the lifetime costs and effects of the intervention.  Costs were calculated in 2013/14 
UK pounds, inflated where appropriate using the consumer price index [11]. A discount rate 
of 3.5% was applied for costs and effects [12]. 
 
The higher an individual’s BMI, the more likely they are to develop obesity-related co-
morbidities such as diabetes, CHD, stroke, sleep apnoea and some forms of cancers. Due to 
lack of accurate data on other risk factors, the model focused on the increased risk of 
developing diabetes, CHD, stroke and colon cancer, for which there are data on the risks of 
these conditions by BMI. However, while there are reasonable data on the risks of each 
individual co-morbidity and BMI, there is no data on the association between BMI and multiple 
combinations of these co-morbidities. Therefore, the possibility of having multiple co-
morbidities at the same time was not incorporated in the model. This assumption is likely to 
mean that we have underestimated the burden associated with obesity-related co-morbidities. 
 
In the model, a hypothetical cohort of 1,000 adolescents with severe obesity underwent 
bariatric surgery (RYGB or SG) or no surgery. Effects of surgery were modelled as a reduction 
in BMI and consequent reduction in the development of diabetes, CHD, stroke and colon 
cancer. Transitions between BMI levels were modified following bariatric surgery in order to 
reflect the reduction in BMI observed following surgery. The initial decline in BMI due to 
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surgery was taken from the cohort of 18 adolescents undergoing surgery at University College 
London Hospitals (UCLH). We then included an annual increment (obesity drift) to update an 
adolescent’s BMI over time. Published literature shows that BMI is predicted to increase by 
+0.12 kg/m2 per year in patients aged <45 years [13], +0.07kg/m2 per year for age between 45 
and 65 years and -0.14 kg/m2 per year for age>=65 years [14].  
Transitions into long-term co-morbidities were also modified following bariatric surgery, 
consistent with the benefits of bariatric surgery.  
 
Our assumption in the no surgery group was for BMI to stay constant with no incremental drift; 
the assumption of no incremental drift potentially underestimates lifetime BMI in the no 
surgery group. However, a systematic review shows that interventions that do not include 
surgery generally have very limited impact on the body weight in adults with severe or morbid 
obesity [15]. 
 
Parameter Estimates and Data Sources 
Parameter values for the model were taken from a variety of secondary sources.  
 
The correlation between BMI and annual risk of developing diabetes, CHD, stroke and colon 
cancer were calculated based on estimates from the DYNAMO-HIA project [16]. This study 
provides estimates of the relative risks of defined diseases according to BMI status (given as 
per unit increase from BMI 22=1.0; we then adjusted this estimate for the mean BMI of the 
adult UK population (BMI 27=1.0) [17]). The risk of co-morbidities was adjusted according to 
age, gender and prevalence of diabetes, CHD and stroke based on information provided by a 
large representative population health survey, the 2013 Health Survey for England (HSE) [16], 
complemented by published source for colon cancer [18].    
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Mortality due to co-morbidities was taken from UK National Life tables 2011-2013 for 
diabetes, CHD, stroke and colon cancer [19].  The yearly probability of diabetes, CHD, stroke 
and colon cancer were obtained from the actual number of deaths [19] and disease disability 
[17]. Information on length of life associated with each health state was taken from published 
literature [20-23], interpolated to reflect the remaining length of life after each cycle. 
Mortality rates of adolescents with severe obesity in the “no co-morbidity” health state are 
assumed to be equivalent to those observed in the general population. On the one hand, this 
may underestimate the mortality risk in this group as the mean BMI in the general population 
is lower than in our sample. On the other hand, the general population sample will include 
people with co-morbidities.  
 
Health-Related Quality of Life  
We used three published sources to estimate: (1) baseline utilities for people with obesity; (2) 
utilities associates with changes in BMI over time; and (3) utilities associated with each co-
morbidity.  For (1) we used a published study that explored the relationship between BMI and 
health related quality of life (HRQoL), measured using the EQ-5D for men and women within 
a national population sample [24]. For (2) we used a published study documenting changes in 
utility associated with the incremental drift in BMI over time: this study reported that a one-
unit decrease in BMI over 1-year period was associated with a 0.0170 gain in utility [25]. For 
(3) multipliers were applied to the utility weights for adolescents with co-morbidities included 
in the model using a catalogue of EQ-5D scores for a variety of health conditions [26]. A utility 
profile was constructed from age of 18 to 100 for every patient in the cohort, assigning a utility 
score of 0 for those who had died. 
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Costs 
Data on resource use and costs associated with bariatric surgery were obtained from UCLH 
Finance Department and included the costs of the procedure (including pre-operative 
preparation) and the costs of 24 months of postoperative care. Costs were based on the average 
costs for each intervention type in the Healthcare Resource Groups (HRGs) costing system. 
 
The direct medical costs for the surgery group were those associated with the intervention and 
a surgical follow-up including the pre-surgical preparation visits (up to 1 year before surgery) 
and follow-up costs (dietetic, physician, psychology and nursing follow-up); these were 
assumed until year 5 post-surgery. From year 6 post-surgery, annual medical costs related to 
weight control were applied, assuming one GP visit per year. 
 
The direct medical costs for the no surgery group were assumed to be the same as those incurred 
pre-intervention in the surgical group, plus regular follow-up for the first year (dietetic, 
psychology and nursing follow-up). After 1 year, no medical costs related to weight control 
were applied. 
 
The annual cost of diabetes, CHD, stroke [27], and colon cancer [28], were obtained from 
published sources.  
 
Cost-Effectiveness Analysis 
The main result of the study was the incremental cost-effectiveness ratio (ICER) of bariatric 
surgery versus no surgery. The ICER was calculated by dividing the incremental costs 
(difference in costs between surgery (RYBG or SG) group and non-surgery group) by 
incremental QALY (difference in QALYs between the two surgery and non-surgery groups).  
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The model was developed using Microsoft Excel 2010 Software [29]. 
 
Sensitivity Analysis 
In order to address parameter uncertainty we used both deterministic and probabilistic 
sensitivity analyses. 
We conducted a series of one-way sensitivity analyses to test the robustness of the cost 
calculation and to determine how changes in certain parameters affected the total cost helping 
in revealing the key drivers of the cost-effectiveness. 
In one-way sensitivity analyses, the ICERs were recalculated when individual parameters were 
varied, including the gain in quality of life per unit of BMI, the intervention costs, the initial 
weight and weight reduction after intervention and the discount rate. The one-way sensitivity 
analysis was performed on individual parameters over minimum and maximum ranges that 
were derived from UCLH data. 
 
We also conducted probabilistic sensitivity analyses (PSA) [30] with 1,000 bootstraps 
replications to assess the robustness of our results to input parameters uncertainty around 
multiple parameters simultaneously. The analyses were performed with appropriate 
distributional assumptions for each variable parametrised related to the nature of the variable. 
The PSA were based on a gamma distribution for intervention, medical costs and disutility 
scores, a beta distribution for the quality of life gain associated with BMI reduction, a log-
normal distribution for post-surgical weight loss and obesity drift. The results of the PSA are 
summarised as the probability of each procedure being cost-effective at different willingness-
to-pay (WTP) levels, or threshold for cost-effectiveness, using cost-effectiveness acceptability 
curves [31]. We also used the PSA to generate 95% confidence intervals around the point 
estimates based on the standard error of the values from the 1,000 bootstrap replications. 
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Results 
Participants’ Characteristics 
Data from 18 adolescents who underwent bariatric surgery were analysed. Nine adolescents 
underwent RYBG and nine underwent SG. Mean age of adolescents at time of surgery who 
underwent RYGB was 17.8 years and of those who underwent SG it was 18.7 years. Mean 
BMI (standard deviation, SD) at baseline for those who underwent RYBG was 48.3kg/m2 (SD 
6.2) and for those who underwent SG it was 60.0 kg/m2 (SD 9.3) (Table 1). 
 
Base Case Analysis 
The parameter values for the cost-effectiveness model and their ranges used in sensitivity 
analyses are presented in Table 2. 
 
At one year follow up mean reduction in BMI was 12.28 kg/m2 (SD 2.98) for adolescents who 
had RYGB and 16.16 kg/m2 (SD 9.96) for adolescents who had SG.  
 
Compared with no surgery, males who underwent RYBG were estimated to have 5.57 (95% 
CI 5.55 to 5.59) more QALYs over their lifetime; females were estimated to have 5.66 (95% 
CI 5.64 to 5.67) more QALYs. For SG the difference was 5.50 (95% CI 5.48 to 5.52) for males 
and 5.64 (95% CI 5.63 to 5.65) for females (Table 3).Compared with no surgery, the lifetime 
incremental cost per person of RYGB versus no surgery was £11,245 (95% CI £10,777 to 
£11,413) for males and £11,343 (95% CI £11,172 to £11,514) for females. For SG the figures 
were £10,877 (95% CI £10,707 to £11,046) for males and £10,954 (95% CI £10,782 to 
£11,125) for females (Table 3). The higher costs of surgery were due to the costs of the surgical 
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procedure itself and the costs of pre- and post-operative care. These were offset by the costs of 
treating co-morbidities, which were slightly lower with surgery.  
 
The incremental cost per QALY gained of RYGB versus no surgery was £2,018 (95% CI 
£1,942 to £2,042) for males and £2,005 (95% CI £1,974 to £2,031) for females. The mean 
incremental cost per QALY gained of SG versus no surgery was £1,978 (95% CI £1,954 to 
£2,002) for males and £1,941 (95% CI £1,915 to £1,969) for females (Table 3). 
 
Sensitivity Analysis 
One-way sensitivity analyses were conducted for the most influential variables with the higher 
impact on the model’s results. The results did not vary appreciably in the sensitivity analyses. 
The incremental cost per QALY gained remained under £5,000 for bariatric surgery versus no 
surgery for both types of procedures when all the parameter values were varied within plausible 
limits (Table 4 and Online supplementary Table S1 and Table S2).Results of the probabilistic 
cost-effectiveness analysis are presented in Online Supplement-Table S3. The cost-
effectiveness acceptability curves for bariatric surgery compared to no surgery indicate the 
probability of bariatric surgery being more cost-effective than the no surgery for a range of 
values a decision maker is willing to pay for an additional unit of health gain. 
 
At NICE’s recommended threshold of £20,000 per QALY gained [32], the probability of 
bariatric surgery being cost-effective is >90% (Figure 2).  
 
Discussion 
Our study shows that bariatric surgery in adolescents with severe obesity is highly cost-
effective over the long term and also improves quality-adjusted life years. Costs of surgery are 
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significantly higher than for the non-surgical group; however the benefits of improved quality 
and length of life result in surgery being highly cost-effective. 
 
Few studies of bariatric surgery in adolescents that include an economic evaluation have been 
published, all from Australia or the US [33, 37]. Our study is the first published from the 
perspective of a national health service. Caution is needed when comparing results of cost-
effectiveness studies due to variations with respect to type of surgery, population of young 
people, perspective of the study, time horizon, quality of life instrument and discount rate used. 
 
A meta-analysis of bariatric surgery published in 2011[33] identified three papers [34-36] 
based on the ACE-Obesity (Assessing Cost-Effectiveness in Obesity) which undertook 
economic modelling and reported that laparoscopic adjustable gastric band (LAGB) was cost-
effective in Australian adolescent population (cost/DALY $AU 4,400). Another more recent 
study of American adolescents from a single centre [37] concluded that bariatric surgery 
(RYGB) may be cost-effective when evaluated over a long period of time (ICER under a 
threshold of $100,000/QALY from year 4).  
 
Our findings are comparable with those reported for adults. A systematic review of bariatric 
surgery in adults concluded that bariatric surgery was cost-effective in comparison with non-
surgical interventions for those with a higher range of BMI [7]. 
 
Strengths and weaknesses 
We used an unselected cohort from the largest UK centre undertaking adolescent bariatric 
surgery, together with modelled data from nationally representative surveys and authoritative 
data sources. Our estimates of cost-effectiveness are likely to be conservative. We accounted 
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for likely upward BMI drift after surgery using data taken from studies of obese adults after 
bariatric surgery, but did not include drift in the non-surgery group, although this is likely. 
Quality of life estimates were taken from samples of morbidly obese adults. We included costs 
of follow-up after surgery up to 5 years, but did not include any follow-up costs for the non-
surgery group past 1 year. Obesity is recognised as being a risk factor for co-morbidities other 
than those included in the model (diabetes, CHD, stroke and colon cancer) and thus our model 
likely underestimates the impact of obesity.  Together, these suggest that our findings likely 
underestimate the cost-effectiveness of surgery. 
We undertook a long-term evaluation of bariatric surgery. Findings were further strengthened 
by sensitivity analyses showing that large change in cost or utility estimates did not change the 
main conclusions. 
Our findings are subject to a number of limitations. The main limitation is that data on the 
impact of surgery on BMI was available for only 18 adolescents. While this number is small, 
it is the largest UK cohort at the time. Further research would be beneficial in future with a 
larger cohort of UK patients. Our model only captures the direct costs. Cost owing to loss of 
productivity caused by obesity and its co-morbidities were not included in the analysis. This is 
a conservative assumption as many of the costs associated with obesity may fall on individuals 
as well as society.  
 
Also, medication costs were not incorporated in the model. 
 
While we had a precise estimate of the costs of bariatric surgery at UCLH, the lack of empirical 
quality of life data from patients who underwent bariatric surgery could cause uncertainty in 
the model. Future evaluation is needed to measure and incorporate changes in quality of life 
from the adolescent population undergoing bariatric surgery.  
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Costs for procedures were provided by a single centre (UCLH), which has high costs due to 
being a central London teaching hospital. Costs shown here therefore may be higher than in 
other hospitals; however, this would lead to an underestimate of the cost-effectiveness of   
surgery. Further, our assumptions regarding post-operative resource use may be excessively 
high.  Again, this suggests that the model provides a conservative estimate of the cost-
effectiveness of the bariatric surgery and potentially overestimates the overall impact of 
obesity. 
 
Conclusions  
Bariatric surgery of adolescents with severe obesity is a cost-effective alternative to no 
surgery from the perspective of the UK’s NHS. 
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Table1. Descriptive statistics of adolescents undergoing bariatric surgery  
Clinical variable  
Roux en Y Gastric 
Bypass 
Sleeve Gastrectomy 
n=9 n=9 
      
Females (%) 56% 44% 
Age (years)     
Mean 17.8 18.7 
SD 1.2 1.2 
Age range (years) 16-19 17-20 
BMI at baseline (kg/m2)     
Mean 48.3 60.0 
SD 6.2 9.3 
Weight at baseline (kg)     
Mean 142.2 170.3 
SD 21.1 42.3 
Height at baseline (cm)     
Mean 171.3 168.0 
SD 7.3 16.3 
SD=standard deviation; BMI = body mass index 
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Table 2. Input parameters for cost-effectiveness model 
Parameter 
Base 
case 
Standard 
error 
Uncertainty ranges  
Uncertainty 
distribution 
Sources for input 
parameters 
Cost of RYGB £7,100 £32 £5,619 £8,023 Gamma* UCLH data 
Cost of RYGB follow-up 1st year  £2,524 £601 £315 £4,982 Gamma^ Assumption 
Cost of RYGB follow-up 2nd-5th year  £445 £106 £56 £879 Gamma^ Assumption 
Cost of RYGB follow-up from year 6 £46 £5 £41 £51 Gamma Curtis L. 
Cost of SG £7,312 £134 £5,787 £8,263 Gamma* UCLH data 
Cost of SG follow-up 1st year £2,168 £512 £575 £5,030 Gamma^ Assumption 
Cost of SG follow-up 2nd-5th year £383 £90 £102 £888 Gamma^ Assumption 
Cost of SG follow-up from year 6 £46 £5 £41 £51 Gamma PSSRU 
Cost diabetes per year £1,006 £101 £906 £1,107 Gamma Anokye N et al. 
Cost CHD per year £498 £50 £448 £548 Gamma Anokye N et al. 
Cost stroke per year £2,475 £247 £2,227 £2,722 Gamma Anokye N et al. 
Cost colon cancer per year £8,229 £823 £7,406 £9,052 Gamma Cancer Research UK 
Utility male (BMI 30-39.9kg/m2) 0.82 0.082 0.74 0.90 Beta Macran S 
Utility female (BMI 30-39.9kg/m2) 0.78 0.078 0.70 0.86 Beta Macran S 
Utility male (BMI 40-49.9kg/m2) 0.56 0.056 0.50 0.62 Beta Assumption 
Utility female (BMI 40-49.9kg/m2) 0.52 0.052 0.47 0.57 Beta Assumption 
Utility male (BMI >=50kg/m2) 0.30 0.030 0.27 0.33 Beta Assumption 
Utility female (BMI >=50kg/m2) 0.26 0.026 0.24 0.29 Beta Assumption 
Utility gain for 1 unit BMI reduction 0.017 0.0017 0.015 0.019 Beta Hakim Z et al. 
Disutility score age -0.0003 0.0002 -0.0003 -0.0003 Gamma Sullivan PW et al. 
Disutility score diabetes -0.0714 0.0048 -0.0643 -0.0785 Gamma Sullivan PW et al. 
Disutility score CHD -0.0627 0.0131 -0.0564 -0.0690 Gamma Sullivan PW et al. 
Disutility score stroke -0.0330 0.0223 -0.0297 -0.0363 Gamma Sullivan PW et al. 
Disutility score colon cancer -0.0674 0.0172 -0.0607 -0.0741 Gamma Sullivan PW et al. 
Obesity drift up to 45 years 0.12 0.012 0.11 0.13 Log-normal Baum CL et al. 
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Obesity drift 45-65 years 0.07 0.007 0.06 0.08 Log-normal Borg S et al. 
Obesity drift over 65years -0.17 -0.017 -0.15 -0.19 Log-normal Borg S et al. 
Mean BMI at 1 year RYGB 34.07 3.54 30.58 38.86 Log-normal^ UCLH data 
Mean BMI at 1 year SG   43.88 4.13 30.92 54.83 Log-normal^ UCLH data 
Discount rate for cost (%) 3.5%   0.0% 5.0%   NICE  
Discount rate for outcomes (%) 3.5%   0.0% 5.0%   NICE  
* Lower/Upper Quartile Unit Cost as in National Schedule of Reference Costs - Year 2013-14; ^ Lower/Upper values based on calculations; all others ± 10% 
around the mean (except discount rate values); RYGB = Roux en Y Gastric Bypass; SG = Sleeve Gastrectomy; CHD = coronary heart disease; BMI = body 
mass index. 
 
 
 
 
 
 
 
 
 
25 
 
Table 3. Mean cost (2013-2014 UK£), Quality Adjusted Life years (QALY) and Incremental Cost-Effectiveness Ratio (ICER) over 
lifetime by gender and bariatric surgery type 
    Males Females 
    Mean 95% CI Mean 95% CI 
Roux en Y Gastric Bypass 
Surgery £7,100 (£7,037; £7,162) £7,100 (£7,049; £7,576) 
No co-morbidities £4,825 (£4,765; £4,886) £4,879 (£4,819; £4,939) 
Diabetes £1,421 (£1,417; £1,424) £1,025 (£1,022; £1,027) 
CHD £206 (£205; £206) £150 (£150; 151) 
Stroke £706 (£704; £708) £616 (£614;£ 617) 
Colon cancer £402 (£401; £403) £333 (£332; £334) 
Total cost £14,660 (£14,183; £14,836) £14,102 (£13,925; £14,279) 
QALY 18.84 (18.79; 18.89) 18.30 (18.25; 18.34) 
No surgery 
Surgery - - - - 
No co-morbidities £96 (£93; £96) £96 (£93; £98) 
Diabetes £1,912 (£1,908; £1,916) £1,469 (£1,466; £1,472) 
CHD £238 (£237; £239) £184 (£183; £184) 
Stroke £752 (£750; £754) £675 (£673; £677) 
Colon cancer £417 (£416; £418) £336 (£335; £337) 
Total cost £3,414 (£3,406; £3,423) £2,759 (£2,753; £2,765) 
QALY 13.27 (13.24; 13.30) 12.64 (12.61; 12.67) 
Differences 
Total cost £11,245 (£10,777; £11,413) £11,343 (£11,172; £11,514) 
QALY 5.57 (5.55; 5.59) 5.66 (5.64; 5.67) 
ICER   £2,018 (£1,942; £2,042) £2,005 (£1,974; £2,031) 
            
    Mean 95% CI Mean 95% CI 
Sleeve Gastrectomy Surgery £7,312 (£7,037; £7,362) £7,312 (£7,049; £7,576) 
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No co-morbidities £4,232 (£4,181; £4,284) £4,287 (£4,236; £4,339) 
Diabetes £1,869 (£1,865; £1,873) £1,430 (£1,427; £1,433) 
CHD £236 (£235; £237) £181 (£181; £182) 
Stroke £749 (£747; £751) £670 (£669; £672) 
Colon cancer £416 (£415; £417) £336 (£335; £337) 
Total cost £14,815 (£14,637; £14,994) £14,217 (£14,038; £14,396) 
QALY 12.47 (12.44; 12.51) 11.82 (11.79; 11.85) 
No surgery 
Surgery - - - - 
No co-morbidities £96 (£93; £98) £96 (£93; £98) 
Diabetes £2,357 (£2,351; £2,362) £1,894 (£1,890; £1,898) 
CHD £267 (£266; £267) £211 (£210; £211) 
Stroke £794 (£791; £796) £727 (£725; £729) 
Colon cancer £426 (£425; £428) £337 (£336; £338) 
Total cost £3,939 (£3,930; £3,948) £3,264 (£3,256; £3,271) 
QALY 6.98 (6.96; 6.99) 6.18 (6.16; 6.20) 
Differences 
Total cost £10,877 (£10,707; £11,046) £10,954 (£10,782; £11,125) 
QALY 5.50 (5.48; 5.52) 5.64 (5.63; 5.65) 
ICER   £1,978 (£1,954; £2,002) £1,941 (£1,915; £1,969) 
CI = confidence interval; CHD = coronary heart disease 
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Table 4. Results of univariate sensitivity analysis 
  Roux en Y Gastric Bypass  Sleeve Gastrectomy  
Scenario Males Females Males Females 
Base case £2,018 £2,005 £1,978 £1,941 
Surgery cost: high £2,183 £2,168 £2,151 £2,109 
Surgery cost: low £1,752 £1,743 £1,701 £1,670 
Baseline utility weight: high £1,486 £1,493 £1,586 £1,579 
Baseline utility weight: low £3,141 £3,049 £2,628 £2,518 
Utility weight associated with changes in BMI over time: high £2,669 £2,599 £2,283 £2,194 
Utility weight associated with changes in BMI over time: low £1,622 £1,632 £1,745 £1,740 
BMI at baseline: high £914 £905 £1,978 £1,941 
BMI at baseline: low -£15,641 -£14,538 -£14,374 -£14,046 
Reduction in BMI: high £1,973 £1,965 £857 £850 
Reduction in BMI: low £2,075 £2,057 -£14,345 -£14,007 
Cost discount rate: high £2,006 £2,240 £1,968 £2,216 
Cost discount rate: low £1,920 -£385 £1,898 -£778 
Outcomes discount rate: high £2,609 £2,283 £2,554 £2,150 
Outcomes discount rate: low £861 £1,761 £849 £1,883 
All figures are incremental cost-effectiveness ratios (incremental cost per QALY gained) comparing surgery vs. no surgery. See Online supplementary 
material (Table 1 and Table 2) for detailed results for every scenario; BMI = body mass index
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Fig 1. Structure of the Markov model 
 
  
 
 
CHD = coronary heart disease 
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Fig 2. Cost-effectiveness acceptability curves  
 
RYGB = Roux en Y Gastric Bypass; SG = Sleeve Gastrectom
30 
 
Table S1. Sensitivity analysis for Roux en Y Gastric Bypass intervention 
Scenario Intervention 
Males Females 
Costs  Δ Costs  QALY Δ QALY ICER Costs  Δ Costs  QALY Δ QALY ICER 
Base case No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 14,660   £ 11,245  18.84 5.57  £   2,018   £ 14,102   £ 11,343  18.30 5.66  £   2,005  
Costs                       
Surgery cost                       
Upper values No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 15,583   £ 12,168  18.84 5.57  £   2,183   £ 15,025   £ 12,266  18.30 5.66  £   2,168  
Lower values No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 13,179   £   9,765  18.84 5.57  £   1,752   £ 12,621   £   9,862  18.30 5.66  £   1,743  
Utility weight                       
Utility weight of BMI 30-39.9kg/m2                       
Upper values No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 14,660   £ 11,245  20.84 7.57  £   1,486   £ 14,102   £ 11,343  20.24 7.60  £   1,493  
Lower values No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 14,660   £ 11,245  16.85 3.58  £   3,141   £ 14,102   £ 11,343  16.36 3.72  £   3,049  
Utility weight of BMI 40-49.9kg/m2                       
Upper values No surgery  £   3,414    14.36      £   2,759    13.93     
  Surgery  £ 14,660   £ 11,245  18.84 4.21  £   2,669   £ 14,102   £ 11,343  18.30 4.36  £   2,599  
Lower values No surgery  £   3,414    11.91      £   2,759    11.35     
  Surgery  £ 14,660   £ 11,245  18.84 6.93  £   1,622   £ 14,102   £ 11,343  18.30 6.95  £   1,632  
BMI                       
BMI at baseline (39-57kg/m2)                       
39kg/m2 No surgery  £   2,938    19.63      £   2,320    19.11     
  Surgery  £ 14,660   £ 11,721  18.84 -0.79 -£ 14,863   £ 14,102   £ 11,782  18.30 -0.81 -£ 14,538  
57kg/m2 No surgery  £   3,817    6.99      £   3,145    6.19     
  Surgery  £ 14,660   £ 10,843  18.84 11.86  £      914   £ 14,102   £ 10,957  18.30 12.11  £      905  
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Reduction in BMI (20%-37%) after surgery                       
20% reduction No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 14,923   £ 11,509  18.81 5.55  £   2,075   £ 14,341   £ 11,582  18.27 5.63  £   2,057  
37% reduction No surgery  £   3,414    13.27      £   2,759    12.64     
  Surgery  £ 14,455   £ 11,040  18.86 5.60  £   1,973   £ 13,920   £ 11,161  18.32 5.68  £   1,965  
Discount rate                        
Costs                       
0% No surgery  £ 18,787    13.27      £ 16,278    12.64     
  Surgery  £ 29,488   £ 10,701  18.84 5.57  £   1,920   £ 14,102  -£ 2,176  18.30 5.66 -£      385  
5% No surgery  £   1,799    13.27      £   1,427    12.64     
  Surgery  £ 12,977   £ 11,177  18.84 5.57  £   2,006   £ 14,102   £ 12,675  18.30 5.66  £   2,240  
Outcomes                       
0% No surgery  £   3,414    31.24      £   2,759    30.84     
  Surgery  £ 14,660   £ 11,245  44.30 13.06  £      861   £ 27,080   £ 24,321  44.65 13.81  £   1,761  
5% No surgery  £   3,414    10.18      £   2,759    9.62     
  Surgery  £ 14,660   £ 11,245  14.49 4.31  £   2,609   £ 12,674   £   9,915  13.96 4.34  £   2,283  
QALY = quality adjusted life year; ICER = incremental cost-effectiveness ratio; BMI = body mass index 
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Table S2. Sensitivity analysis for Sleeve Gastrectomy intervention 
Scenario Intervention 
Males Females 
Costs  Δ Costs  QALY Δ QALY ICER Costs  Δ Costs  QALY Δ QALY ICER 
Base case No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 14,815   £ 10,877  12.47 5.50  £   1,978   £ 14,217   £ 10,954  11.82 5.64  £   1,941  
Costs                       
Surgery cost                       
Upper values No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 15,766   £ 11,827  12.47 5.50  £   2,151   £ 15,168   £ 11,904  11.82 5.64  £   2,109  
Lower values No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 13,290   £   9,351  12.47 5.50  £   1,701   £ 12,692   £   9,428  11.82 5.64  £   1,670  
Utility weight                       
Utility weight of BMI 40-49.9kg/m2                       
Upper values No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 14,815   £ 10,877  13.83 6.86  £   1,586   £ 14,217   £ 10,954  13.12 6.94  £   1,579  
Lower values No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 14,815   £ 10,877  11.11 4.14  £   2,628   £ 14,217   £ 10,954  10.53 4.35  £   2,518  
Utility weight of BMI >=50kg/m2                       
Upper values No surgery  £   3,939    7.71      £   3,264    6.83     
  Surgery  £ 14,815   £ 10,877  12.47 4.76  £   2,283   £ 14,217   £ 10,954  11.82 4.99  £   2,194  
Lower values No surgery  £   3,939    6.24      £   3,264    5.53     
  Surgery  £ 14,815   £ 10,877  12.47 6.23  £   1,745   £ 14,217   £ 10,954  11.82 6.30  £   1,740  
BMI                       
BMI at baseline (49-77kg/m2)                       
49kg/m2 No surgery  £   3,462    13.26      £   2,804    12.64     
  Surgery  £ 14,815   £ 11,353  12.47 -0.79 -£ 14,374   £ 14,217   £ 11,413  11.82 -0.81 -£ 14,046  
77kg/m2 No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 14,815   £ 10,877  12.47 5.50  £   1,978   £ 14,217   £ 10,954  11.82 5.64  £   1,941  
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Reduction in BMI (9%-48%) after surgery                       
9% reduction No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 15,279   £ 11,341  6.19 -0.79 -£ 14,345   £ 14,664   £ 11,401  5.37 -0.81 -£ 14,007  
48% reduction No surgery  £   3,939    6.98      £   3,264    6.18     
  Surgery  £ 14,120   £ 10,181  18.86 11.89  £      857   £ 13,582   £ 10,318  18.32 12.14  £      850  
Discount rate                        
Costs                       
0% No surgery  £ 20,869    6.98      £ 18,609    6.18     
  Surgery  £ 31,306   £ 10,437  12.47 5.50  £   1,898   £ 14,217  -£ 4,392  11.82 5.64 -£      778  
5% No surgery  £   2,106    6.98      £   1,706    6.18     
  Surgery  £ 12,926   £ 10,820  12.47 5.50  £   1,968   £ 14,217   £ 12,511  11.82 5.64  £   2,216  
Outcomes                       
0% No surgery  £   3,939    15.99      £   3,264    14.61     
  Surgery  £ 14,815   £ 10,877  28.80 12.82  £      849   £ 29,022   £ 25,758  28.29 13.68  £   1,883  
5% No surgery  £   3,939    5.39      £   3,264    4.74     
  Surgery  £ 14,815   £ 10,877  9.65 4.26  £   2,554   £ 12,588   £   9,325  9.08 4.34  £   2,150  
QALY = quality adjusted life year; ICER = incremental cost-effectiveness ratio; BMI = body mass index 
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Table S3. Probabilistic cost-effectiveness analyses 
  Males Females 
  Mean  (95%CI) QALY (95%CI) Mean  (95%CI) QALY (95%CI) 
Roux en Y Gastric Bypass £14,706 (£14,664; £14,747) 19.10 (18.96; 19.24) £14,123 (£14,083; £14,163) 18.62 (18.48; 18.76) 
No surgery £3,410 (£3,397; £3,422) 13.97 (13.89; 14.06) £2,754 (£2,744; £2,764) 13.28 (13.20; 13.36) 
Differences £11,296 (£11,255; £11,337) 5.13 (4.97; 5.29) £11,369 (£11,329; £11,408) 5.34 (5.18; 5.50) 
ICER 2,201 (£10; £4,393) 2,129 (£1,186; £3,071) 
                  
  Mean  (95%CI) QALY (95%CI) Mean  (95%CI) QALY (95%CI) 
Sleeve Gastrectomy £14,819 (£14,782; £14,855) 13.49 (13.29; 13.70) £14,229 (£14,193; £14,265) 13.01 (12.81; 13.21) 
No surgery £3,926 (£3,910; £3,942) 7.70 (7.66; 7.75) £3,268 (£3,255; £3,281) 6.87 (6.83; 6.91) 
Differences £10,893 (£10,859; £10,928) 5.79 (5.58; 6.00) £10,961 (£10,927; £10,996) 6.14 (5.94; 6.35) 
ICER 1,882 (£1,637; £2,126) 1,784 (£1,580; £1,989) 
QALY = quality adjusted life year; ICER = incremental cost-effectiveness ratio 
 
 
 
 
 
 
